Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Elvitegravir

🥰Excellent
Catalog No. T2332Cas No. 697761-98-1
Alias JTK-303, GS-9137, EVG, D06677

Elvitegravir (JTK-303) is a Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor. The mechanism of action of elvitegravir is as an HIV Integrase Inhibitor, and Cytochrome P450 2C9 Inducer.

Elvitegravir

Elvitegravir

🥰Excellent
Purity: 99.73%
Catalog No. T2332Alias JTK-303, GS-9137, EVG, D06677Cas No. 697761-98-1
Elvitegravir (JTK-303) is a Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor. The mechanism of action of elvitegravir is as an HIV Integrase Inhibitor, and Cytochrome P450 2C9 Inducer.
Pack SizePriceAvailabilityQuantity
5 mg$47In Stock
10 mg$79In Stock
25 mg$155In Stock
50 mg$298In Stock
100 mg$486In Stock
1 mL x 10 mM (in DMSO)$47In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Elvitegravir"

Select Batch
Purity:99.73%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Elvitegravir (JTK-303) is a Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor. The mechanism of action of elvitegravir is as an HIV Integrase Inhibitor, and Cytochrome P450 2C9 Inducer.
Targets&IC50
HIV-2 (EHO):2.8 nM, HIV-2 (ROD):1.4 nM, HIV-1 (IIIB):0.7 nM
In vivo
Elvitegravir inhibits the replication of MLV infection with an IC50 of 5.8 nM and also suppresses the primate retrovirus SIV with an IC50 of 0.5 nM, demonstrating its activity against multiple retroviruses due to IN inhibitor properties. It inhibits integrase activity with an IC50 of 6 nM and affects PBMC and PA with IC50 values of 0.89 nM and 20 nM, respectively. Additionally, Elvitegravir blocks the synthesis of chain transfer products with an IC50 of 54 nM by inhibiting integration via IN-regulated chain transfer. EVG exhibits antiviral activity without serum, with IC50 values ranging from 0.3 to 0.9 nM, targeting peripheral blood mononuclear cells and effectively inhibiting HIV-1 and HIV-2.
Cell Research
Elvitegravir (EVG) is prepared in DMSO and stored, and then diluted with appropriate medium before use[1]. MT-2 cells (2×105 cells) are infected with HIV-1 IIIB and then cultured in the presence of 0.5 nM or 0.1 nM Elvitegravir. Cultures are incubated at 37°C until an extensive cytopathic effect (CPE) is observed, and the culture supernatant is then harvested for further passage in fresh MT-2 cells. The concentration of Elvitegravir is increased when a significant CPE is observed. At the indicated passages, proviral DNA is extracted from infected MT-2 cells and then subjected to PCR, followed by direct population-based sequencing. Susceptibility to Elvitegravir at the indicated passages is determined using the MAGI assay or p24 production[1].
AliasJTK-303, GS-9137, EVG, D06677
Chemical Properties
Molecular Weight447.88
FormulaC23H23ClFNO5
Cas No.697761-98-1
SmilesCOC1=C(CC2=CC=CC(Cl)=C2F)C=C2C(=O)C(=CN(C(CO)C(C)C)C2=C1)C(O)=O
Relative Density.1.357 g/cm3 (Predicted)
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 82 mg/mL (183.1 mM)
Ethanol: 33 mg/mL (73.7 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
Solution Preparation Table
Ethanol/DMSO
1mg5mg10mg50mg
1 mM2.2327 mL11.1637 mL22.3274 mL111.6370 mL
5 mM0.4465 mL2.2327 mL4.4655 mL22.3274 mL
10 mM0.2233 mL1.1164 mL2.2327 mL11.1637 mL
20 mM0.1116 mL0.5582 mL1.1164 mL5.5819 mL
50 mM0.0447 mL0.2233 mL0.4465 mL2.2327 mL
DMSO
1mg5mg10mg50mg
100 mM0.0223 mL0.1116 mL0.2233 mL1.1164 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Elvitegravir | purchase Elvitegravir | Elvitegravir cost | order Elvitegravir | Elvitegravir chemical structure | Elvitegravir in vivo | Elvitegravir formula | Elvitegravir molecular weight